AbCellera Biologics Inc. Operating Income Loss

• AbCellera Biologics Inc. showed an increase of +31.0% in Operating Income Loss from 2024 to 2025.
• This data is from AbCellera Biologics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), AbCellera Biologics Inc.'s Operating Income Loss has declined by 5,173.3%.
• Historical annual values: Fiscal year 2025: -$217.10 million | Fiscal year 2024: -$314.77 million | Fiscal year 2023: -$237.21 million | Fiscal year 2022: $216.51 million | Fiscal year 2021: $204.41 million | Fiscal year 2020: $156.03 million | Fiscal year 2019: -$4.12 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026